REDWOOD CITY, CA / ACCESSWIRE / October 3, 2023 / Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced the filing of a patent application for its groundbreaking Biotres device. This patent protects Biotres' proprietary 3 channel technology, multiple sensors, architecture and compact form factor, a combination that has never been done before. Up until now, compact devices have lacked multiple channels, reducing the quality of diagnosis. Biotres is a cutting-edge invention that marks a significant advancement in remote patient monitoring and cardiac care. This filing expands the Company's IP portfolio while increasing market barriers.

Dr. Waqaas Al-Siddiq, CEO of Biotricity, commented on the patent filing, stating, "This filing is part of our broader strategy of continually expanding our IP portfolio with trade secrets and patents. As we consistently innovate and expand our IP and FDA 510(k) portfolios, we are not only winning market share and protecting our IP but continuously increasing the barriers to entry."

The filing of Biotres patent serves as a powerful testament to Biotricity's relentless pursuit of healthcare innovation, where it consistently explores the frontiers of technology to redefine the cardiac care landscape. The company plans to continue to file patents as part of its IP strategy and expects to file two additional patents within the next year. This patent application marks another significant milestone in Biotricity's journey, complementing its existing patent portfolio.

The Biotres device represents a revolutionary leap forward in the field of cardiac technology. This cutting-edge device redefines cardiac monitoring by providing continuous, real-time data on vital signs, including heart rate, 3 channels of ECG, and activity levels, enabling early detection and proactive management of cardiac conditions for both patients and healthcare providers.

Biotres is the first of its kind, a compact 3-channel connected cardiac monitor that addresses the lack of multiple ECG channels, multiple sensors, rechargeability and connectivity within a compact patch form factor. It offers up to 30 days of recording, while its wireless connectivity ensures automated data offloading and remote ECG views, reducing results wait time from the conventional 2-week period to 3 days or less. Physicians can remotely access ECG data, and patients can easily report symptoms via an intuitive app, facilitating faster clinician response. With Biotres, Biotricity is not only innovating but also establishing a new industry standard, revolutionizing cardiac monitoring to enhance patient outcomes, increase patient safety and empower healthcare providers.

To learn more about our cutting-edge solutions in cardiac care, visit www.biotricity.com, where Biotres is readily available for purchase.

About Biotricity Inc.

Biotricity, Inc. is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts

Investor Relations
Biotricity Investor Relations
Investors@biotricity.com

SOURCE: Biotricity, Inc.

View source version on accesswire.com:
https://www.accesswire.com/789547/biotricity-announces-patient-filing-for-cutting-edge-biotres-device